Oncology · Hematology · 3 h ago
Frontline BTK inhibitors linked to higher response and longer PFS in PCNSL
A retrospective study of 131 patients with newly diagnosed primary CNS lymphoma compared BTK inhibitor–based frontline induction with conventional therapy. After adjustment for baseline covariates, BTK inhibitor–based treatment was associated with higher response rates and improved progression-free survival, but not a statistically significant overall-survival difference.
- Retrospective comparison included 131 newly diagnosed patients.
- BTKi-based therapy was associated with higher complete response odds.
- Adjusted progression-free survival favored BTKi-based therapy.
- Overall-survival difference was not statistically significant.
High-dose methotrexate–based immunochemotherapy remains a standard frontline approach for primary CNS lymphoma (PCNSL), but relapse and suboptimal outcomes remain concerns. This retrospective study evaluated 131 newly diagnosed patients: 85 received BTK inhibitor (BTKi)–based induction and 46 received conventional therapy. Investigators used multiple imputation and inverse probability of treatment weighting to balance baseline covariates.
In the primary adjusted analysis, BTKi-based therapy was associated with longer progression-free survival (hazard ratio, 0.57; 95% CI, 0.32–1.00; P=0.048) and higher odds of complete response (odds ratio, 5.50; 95% CI, 2.25–13.47; P<0.001). Odds of objective response were also higher (odds ratio, 2.59; 95% CI, 1.05–6.36; P=0.038). The overall-survival difference was not statistically significant (hazard ratio, 0.65; 95% CI, 0.31–1.38; P=0.263).
The findings suggest an association between frontline BTKi-based regimens and improved response and progression-free survival, but do not establish causality or an overall-survival benefit. The retrospective design leaves potential for residual confounding; the source provides no regimen-level details or full-text limitations.
In practice
For patients with newly diagnosed primary CNS lymphoma, this retrospective comparison found that BTK inhibitor–based frontline induction was associated with higher response rates and longer progression-free survival than conventional therapy after statistical adjustment. The study does not establish that BTK inhibitors caused these outcomes, and it found no statistically significant overall-survival difference. These findings are promising but are not sufficient on their own to justify changing treatment practice; the source does not provide regimen-level details or the full text.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Blood Advances: Frontline Bruton tyrosine kinase inhibitors are associated with improved response and PFS in primary CNS lymphoma ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.